Loading
Head and Neck Neoplasms / Head and Neck Cancer / Neoplasm Recurrence, Local · Journal article
Human Vaccines & Immunotherapeutics · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This Markov model estimates that finotonlimab combined with chemotherapy costs $112,384.47/QALY compared to chemotherapy alone in R/M HNSCC in China, exceeding a willingness-to-pay threshold of $40,744/QALY. Cost reduction through price discount could bring the intervention near cost-effectiveness thresholds. The analysis is conditional on trial-derived survival data and Chinese healthcare cost and utility assumptions.
Decision-analytic Markov model with one-way sensitivity analysis, probabilistic sensitivity analysis, and scenario analysis. Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the Chinese healthcare setting; model parameters informed by SCT-I10A-B301 trial.. Intervention: Finotonlimab combined with chemotherapy. Compared with: Chemotherapy alone. Analysis conducted from the viewpoint of the Chinese healthcare system..
Finotonlimab + chemotherapy incremental cost $26,072.18 higher than chemotherapy alone ($36,996.99 vs $10,924.81) Quality-adjusted life-year gain of 0.23 QALY (0.89 QALY vs 0.66 QALY) Incremental cost-effectiveness ratio $112,384.47/QALY, above willingness-to-pay threshold of $40,744/QALY
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This model suggests finotonlimab combined with chemotherapy is not cost-effective at current pricing relative to Chinese healthcare willingness-to-pay thresholds, though price reduction could alter this conclusion. Clinicians and payers should note the high sensitivity to finotonlimab cost and utility assumptions, and consider this modelling result alongside the underlying trial's efficacy and safety data.
Modelling study based on a single trial's survival data, assessing cost-effectiveness in a specific healthcare system; does not itself evaluate clinical outcomes and depends on external trial evidence and assumptions.
As stated by the source record.
Quoted from the source exactly as published.
This model suggests finotonlimab combined with chemotherapy is not cost-effective at current pricing relative to Chinese healthcare willingness-to-pay thresholds, though price reduction could alter this conclusion. Clinicians and payers should note the high sensitivity to finotonlimab cost and utility assumptions, and consider this modelling result alongside the underlying trial's efficacy and safety data.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
The SCT-I10A-B301 trial demonstrated efficacy and safety of finotonlimab combined with chemotherapy in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). However, the economics of this therapy are unknown. This study aims to assess the cost-effectiveness of incorporating finotonlimab into chemotherapy regimens for R/M HNSCC from the viewpoint of the Chinese healthcare system. A Markov model was developed to evaluate the treatment costs and outcomes of finotonlimab combined with chemotherapy for R/M HNSCC. Survival data were obtained from the SCT-I10A-B301 trial. Considering only direct medical costs, survival data, and utilities. The principal result measures employed were the incremental cost-effectiveness ratio (ICER). To identify how parameter uncertainty affected the model, one-way sensitivity analyses, probabilistic sensitivity analysis (PSA), and scenario studies were carried out. The results showed that the financial burden of finotonlimab, when administered concomitantly with chemotherapy ($36,996.99) was $26,072.18 higher than chemotherapy ($10,924.81) but also increased by 0.23QALY (0.89QALY vs. 0.66QALY), with an ICER of $112,384.47/QALY, which was higher than the willingness to pay (WTP) of $40,744/QALY. The model's sensitivity to three factors was particularly pronounced: the utility of PFS, the utility of PD, and the cost of finotonlimab. Scenario analysis showed that a price reduction for finotonlimab could significantly reduce the ICER to near the WTP threshold. Compared with chemotherapy alone, finotonlimab combined with chemotherapy has been determined to be an ineffective, cost-effective therapeutic strategy for the first-line medical treatment of R/M HNSCC in China, and the price discount of finotonlimab can improve its cost-effectiveness.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.